Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Defined Benefit Plan Disclosure [Line Items] | ||||||
| Revenue | ||||||
| Operating expenses | ||||||
| Research and development | 1,400,564 | 1,045,177 | 2,632,387 | 2,806,644 | 3,517,093 | 1,047,385 |
| General and administrative | 328,995 | 265,553 | 963,642 | 730,186 | 1,046,854 | 473,714 |
| Legal and professional | 1,322,002 | 288,416 | 2,323,013 | 1,072,728 | 1,328,435 | 822,727 |
| Total operating expenses | 3,051,561 | 1,599,146 | 5,919,042 | 4,609,558 | 5,892,382 | 2,343,826 |
| Loss from operations | (3,051,561) | (1,599,146) | (5,919,042) | (4,609,558) | (5,892,382) | (2,343,826) |
| Other income (expense) | ||||||
| Interest income | 2,524 | 20,765 | 38,135 | 56,720 | 79,117 | |
| Finance fee | (104,245) | (104,245) | (189,912) | |||
| Change in fair value of derivative liabilities | 286,316 | 442,900 | 340,405 | 2,118,175 | 2,216,488 | (189,000) |
| Change in fair value of warrant liabilities, as restated | (398,675) | |||||
| Gain on sale of marketable securities | 56,398 | 100,118 | 1,744 | 4,970 | ||
| Change in fair value of marketable securities | (42,898) | 9,606 | (71,568) | 21,134 | 71,568 | |
| Loss on settlement of convertible debt | (762,186) | (43,414) | (833,501) | (477,221) | (477,221) | (1,795,652) |
| Gain on settlement of accounts payable | 328,687 | |||||
| Gain on forgiveness of Paycheck Protection Program note payable | 73,007 | |||||
| Total other expense, as restated | (732,521) | (193,608) | (1,627,286) | (342,665) | (700,341) | (2,652,243) |
| Net loss | $ (3,784,082) | $ (1,792,754) | $ (7,546,328) | $ (4,952,223) | (6,592,723) | (4,996,069) |
| Dividend on Series A Convertible Preferred Stock, as restated | (402,064) | |||||
| Deemed dividend on extinguishment of Series A Convertible Preferred Stock, as restated | (439,427) | |||||
| Deemed dividend on modification of equity-classified warrants, as restated | (941,000) | |||||
| Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated | 31,423 | |||||
| Net loss attributable to common stockholders | $ (6,592,723) | $ (6,747,137) | ||||
| Weighted average common shares outstanding basic | 2,384,177 | 1,969,904 | 2,189,366 | 1,820,006 | 1,866,275 | 1,337,742 |
| Weighted average common shares outstanding diluted | 2,384,177 | 1,969,904 | 2,189,366 | 1,820,006 | 1,866,275 | 1,337,742 |
| Net loss per share - basic | $ (1.59) | $ (0.91) | $ (3.45) | $ (2.72) | $ (3.53) | $ (5.04) |
| Net loss per share - diluted | $ (1.59) | $ (0.91) | $ (3.45) | $ (2.72) | $ (3.53) | $ (5.04) |
| Related Party [Member] | ||||||
| Other income (expense) | ||||||
| Interest expense | $ (2,137) | $ (2,137) | $ (6,825) | $ (6,825) | $ (52,010) | |
| Nonrelated Party [Member] | ||||||
| Other income (expense) | ||||||
| Interest expense | $ (270,538) | $ (623,465) | $ (1,198,738) | $ (1,952,147) | $ (2,484,193) | $ (428,688) |
| X | ||||||||||
- Definition Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends. No definition available.
|
| X | ||||||||||
- Definition Deemed dividend on extinguishment of series preferred stock as restated. No definition available.
|
| X | ||||||||||
- Definition Deemed dividend on modification of equity-classified warrants. No definition available.
|
| X | ||||||||||
- Definition Fair value adjustment of warrant. No definition available.
|
| X | ||||||||||
- Definition Finance fee. No definition available.
|
| X | ||||||||||
- Definition Gain on forgiveness of note payable. No definition available.
|
| X | ||||||||||
- Definition Gain on settlement of accounts payable. No definition available.
|
| X | ||||||||||
- Definition Loss on settlement of convertible debt. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of realized and unrealized gain (loss) on investment in marketable security. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|